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Abstract 
Rheumatoid arthritis (RA)–associated interstitial lung disease (RA-ILD) is an increasingly 
common extra-articular cause of mortality and morbidity in RA. Here, we present the case of an 
82-year-old female suffering from RA-ILD. She presented with a 20-year history of RA with 
new-onset progressively worsening dyspnoea, pyrexia, and dry cough, which were not responsive 
to initial antibiotics. Moreover, she had been on long-term methotrexate, which can cause 
pulmonary disease. Investigations revealed raised inflammatory markers, restrictive lung patterns, 
and radiological features of ILD. She was treated with a tapering course of oral prednisolone and 
home oxygen, which provided some symptomatic improvement. Diagnosis of RA-ILD can be 
challenging due to several contributing factors.  Optimal treatment is controversial, and 
corticosteroids have been widely used but with limited effects. There is evidence directed at 
potential therapeutic benefit from a number of newer agents, which are discussed.   
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Interstitial Lung Disease in 
Rheumatoid Arthritis: A 
Clinical Dilemma 
Introduction 
It is estimated that nearly half of patients with 
rheumatoid arthritis (RA) will develop some 
form of associated respiratory complication in 
their lifetime.1 Of these, interstitial lung 
disease (ILD), characterized by inflammation, 
scarring, and fibrosis of lung tissue, is the only 
complication of RA with an increasing 
prevalence, accounting for about 7% of 
deaths in early RA.2-3 Moreover, the 
medications used in treating RA can cause 
respiratory toxicity and this can complicate 
diagnosis. Despite several recent promising 
developments, the understanding of RA-ILD 
is not well established and its management has 
not been clearly defined. In light of this, we 
report a case of RA-ILD that presents a 
clinical dilemma.   
Case Summary 
An 82-year-old female presented with a 2-
week history of new-onset progressively 
worsening dyspnoea (both on physical 
exertion and at rest), pyrexia (37.8°C), and dry 
cough.  
She was initially treated for community-
acquired pneumonia with antibiotics 
(amoxicillin and clarithromycin 500 mg) but 
without symptomatic improvement. 
Moreover, she had been taking 15 mg of 
methotrexate once weekly for 15 years, which 
was subsequently stopped. She has no known 
drug allergies and is also on regular 
prescriptions of folic acid, calcium tablets, 
naproxen, and alendronate sodium for her 
musculoskeletal problems – long-standing 
seropositive RA (20 years), osteoarthritis, and 
osteoporosis – which have been well 
controlled. She is a non-smoker and is 
normally mobile and active without any 
known respiratory problems. There were no 
previous exposures to asbestos or industrial 
chemicals but she kept cockatiels at home for 
years. On clinical examination, lower lobes of 
the lungs were dull on percussion and bilateral 
inspiratory basal crackles were heard on 
auscultation with decreased air entry into both 
lower lobes. Her respiratory rate was 28 
breaths/minute. Rheumatoid changes were 
also noted on her hands but without any 
digital clubbing. 
Laboratory workup revealed the following: 
 Haemoglobin – 11.1 g/dL (↓) 
 White cell count – 16.2 × 109/L (↑ ) (no evidence of 
eosinophillia) 
 Platelets – 425 × 109/L (↑) 
 INR – 1.4 (↑)  
 C-reactive protein –156.9 mg/L (↑).  
 Arterial blood gases –  
o pH=7.509 (↑),  
o PO2=6.69 kPa (↓) 
o PCO2=4.7 kPa 
o HCO3−=28.2 mmol/L 
o Base excess = 4.5 mmol/L (↑) 
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In addition, her pulmonary function tests 
(PFTs) revealed a restrictive pattern, with a 
reduced diffusing capacity and carbon 
monoxide transfer coefficient (Kco). Her 
oxygen saturation was 78% on room air. A 
chest radiograph (Figure 1 with white arrows) 
revealed increased bilateral patchy airspace 
shadowing as compared to imaging performed 
2 years earlier. Additionally, a high-resolution 
computed tomography (HRCT) scan of the 
thorax (Figure 2) showed bilateral basal 
honeycombing with peripheral patchy 
ground-glass opacification (white arrows) and 
traction bronchiectasis (black arrows). The 
overall clinical picture was consistent with 
interstitial lung disease (pulmonary fibrosis) 
secondary to either rheumatoid arthritis (RA-
ILD) or with possible superimposed 
methotrexate-induced pneumonitis. Other 
differential diagnoses considered were 
aspiration pneumonia, pneumocystis 
infection, acute exacerbation of an existing 
ILD, and hypersensitivity pneumonitis 
(cockatiel exposure).   
She was treated with a tapering course of oral 
prednisolone (20 mg once daily on discharge 
for 4 weeks, followed by 15 mg, then 10 mg) 
and 4 L/minute of home oxygen. On latest 
follow-up, her oxygen saturations improved 
to 97% on 2 L of oxygen. However, PFT 
results remained largely unchanged.  
 
 
Figure 1. Anteroposterior erect chest X-ray 
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Figure 2. HRCT scans of the thorax 
Discussion 
Prevalence and risk factors of RA-ILD 
Despite the high incidence of ILD in patients 
with RA, not every patient is symptomatic. 
McDonagh et al. revealed that ILD has been 
diagnosed in around 20–30% of unselected 
RA populations using HRCT,4 and about half 
of these patients present with respiratory 
symptoms.  
The predictors for RA-ILD include smoking,5-
6 male sex,7 long duration of disease, and the 
presentation of systemic features such as fever 
and weight loss.8 Moreover, increased 
polymorphisms at the HLA-B40 and HLA-
B54 antigen sites have been found in RA-ILD 
and cryptogenic organizing pneumonia 
(COP).9-10 Also, some evidence suggests that 
patients who are seropositive for rheumatoid 
factor and/or possess anti–cyclic citrullinated 
peptide (anti-CCP) antibodies are at risk of 
developing RA-ILD.11-13  
Methotrexate-induced ILD 
Methotrexate, the first-line disease-modifying 
antirheumatic drug (DMARD) in treating RA, 
is known to cause methotrexate-induced 
pulmonary toxicity, of which methotrexate 
pneumonitis (inflammation of lung tissue) is 
common,14 and this can progress to 
pulmonary fibrosis.15 The most significant risk 
factor for developing pneumonitis is pre-
existing pulmonary disease, coupled with a 
baseline diffusing capacity of < 70% 
predicted, which increases the risk of 
developing methotrexate drug toxicity 10-
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fold.16 Other risk factors are listed in Table 2.  
Lung toxicity often occurs after weeks to 
months of low-dose oral methotrexate 
therapy, which has been associated with a 
possible 20% increased mortality rate if 
toxicity occurred within first 6 months of 
treatment.17 In about 90% of patients with 
methotrexate-induced pulmonary toxicity, low 
grade fever has been reported. Also, 
approximately 80% of patients presented with 
a dry, non-productive cough and dyspnoea on 
exertion.17  
Hence, methotrexate should be carefully 
considered in patients with prior RA-ILD18 
due to the increased susceptibility of 
developing pneumonitis, even though 
methotrexate does not directly exacerbate 
ILD.19 Table 1 lists the criteria for diagnosis 
methotrexate pneumonitis.  
 
 
Table 1: Criteria for diagnosis of methotrexate-pneumonitis by Searles and McKendry22
1. Acute- onset dyspnea 
2. Fever >  38° C 
3. Tachypnoea ≥  28 breaths/minute, and dry cough 
4. Radiological evidence of pulmonary interstitial disease or alveolar infiltrates 
5. White blood cell < 15, 000 cells/mm3, with or without eosinophillia 
6. Negative blood and sputum cultures (mandatory) 
7. Restrictive defect and decreased DLCO DLco on PFT 
8. PO2 < 60  mmg  Hg on room air 
9. Histopathology consistent with bronchiolitis or interstitial pneumonitis with giant cells and without 
evidence of infection  
Definite: > or = if 6 or more criteria met; probable if : 5 of 9 criteria met; possible if: 4 of 9 criteria met 
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Table 2: Pulmonary Toxicities Associated with RA medications (Adapted from Hamblin et al20 & Lake et al21) 
Drug Class Pulmonary Toxicity Risk Factors 
Anti-Inflammatory inflammatory Drugs  
NSAIDs  Non-cardiogenic pulmonary oedema  
 Acute eosinophillic pneumonia 
 Interstitial Pneumonitis  
 High-dose treatment 
Corticosteroids  Infection  Dose related 
 Pre-existing severe pulmonary disease 
 Use of biologic DMARDs 
Non-Biologic biologic DMARDs 
Methotrexate   Acute interstitial pneumonia 
 Pulmonary fibrosis 
 Pleural thickening 
 Chronic cough  
Major Risk Factors: 
Carbon monoxide diffusing capacity of 
the lung (DLco) < 70% predicted 
(Increased risk by 10%) 
 Tobacco Abuse > of > 25 pack years  
 Hypoalbuminaemia 
 Previous use of DMARDs  
Minor Risk Factors: 
 RA with pleuropulmonary 
involvement 
Advanced Older age 
 Diabetes Mellitus 
Leflunomide Interstitial Pneumonitis - Acute lung injury and 
Diffuse alveolar damage 
 
 Nodulosis 
 Loading dose of leflunomide 
 Pre-existing ground- glass infiltrates on 
HRCT  
 Previous use of methotrexate 
 Japanese origin 
Sulfasalazine  Eosinophillic pneumonia with peripheral 
eosinophillia and interstitial inflammation with 
or without fibrosis  
 Organizing pneumonia (OP) 
 Non-specific interstitial pneumonia (NSIP) 
 Unknown 
Gold Salts (Rarely used)  Interstitial Pneumonitis  
 Bronchiolitis obliterans with or without 
organizing pneumonia, pulmonary- renal 
syndrome 
 Diffuse alveolar damage 
 Unknown, possible genetic association 
( HLA-B40, HLA-A3, HLA-B35, and 
Dw1 expression) and cumulative 
ingestion >  500 mg gold  
DP-Penicillamine (Rarely used)  Bronchiolitis obliterans 
 Pulmonary- renal syndrome 
 Diffuse alveolar damage 
 Unknown 
Biologic DMARDs 
Anti-TNF-α biologic agents: 
 Etanercept (soluble p75 TNF- α 
receptor fusion protein) 
 Infliximab (dimeric anti-TNF- α) 
 Adalimumab (anti-TNF- α 
monoclonal antibody) 
 Golimumab 
 Certolizumab 
 
 Infection including tuberculosis (pneumonia 
0.8%) 
 Pneumonitis (0.6%) 
o Acute lung injury 
o Usual interstitial pneumonia (UIP) 
o Non-specific interstitial pneumonia 
(NSIP) 
 Non-infectious granulomatous disease 
 New lung nodules 
 
 Low body weight 
 Older age 
 Previous MTX methotrexate 
pneumonitis /lung disease 
 Chest X-ray and Mantoux or 
QuantiFERON Gold before therapy 
Anakinra (IL-1 blocker)  Infection  Unknown 
Rituximab (anti-–B cell 
monoclonal antibody) 
 Organizing pneumonia (Rare) 
 Rapidly progressive pulmonary fibrosis (Rare) 
 Unknown 
Abatacept (selective co-
stimulation modulator preventing 
T-cell CD28 binding) 
 Pneumonitis  Unknown 
Tocilizumab (humanized anti-–
IL-6 receptor monoclonal 
antibody) 
 Rare exacerbation of pre-existing ILD  Pre-existing ILD 
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Diagnosis of ILD 
A thorough clinical evaluation is necessary in 
RA patients presenting with respiratory 
symptoms18 (Figure 3). This is followed by a 
chest radiograph and PFTs to rule out 
common respiratory conditions like infection. 
HRCT of the thorax is the gold-standard 
investigation23 which confirms ILD and 
defines whether it is an extensive disease 
(involving > 20% of total lung volume) or a 
limited disease (< 20% of total lung 
volume).24-25 As seen in our case, the presence 
of bibasal ground-glass infiltrates, increased 
reticular markings, and honeycombing on 
HRCT is highly indicative of ILD.26 Other 
findings may also include pleural involvement, 
rheumatoid nodules, bronchiectasis, 
emphysema, or even bronchiolitis with 
associated consolidation.27-28 Once the 
diagnosis of ILD is made, the challenge of 
determining its aetiology arises, especially in 
the event of an acute clinical decline in lung 
function. If in diagnostic doubt, a video-
assisted thoracoscopic surgery (VATS) biopsy 
should be considered to determine histology.29  
In the case of methotrexate pneumonitis, a 
diffuse interstitial pattern on HRCT has been 
reported in more than 93% of patients; pleural 
thickening and, less commonly, pleural 
effusions are seen in a small number of 
patients.17  
Figure 3. Investigations involved in diagnosing 
RA-ILD (Adapted from Kelly et al18 & Ooi et al29) 
 
 
Although an open lung biopsy would help 
differentiate between RA-ILD and 
methotrexate pneumonitis, this is largely 
unnecessary. In general, methotrexate 
pneumonitis presents with an acute interstitial 
pneumonitis with cellular (lymphocytic) 
interstitial infiltrates with or without 
granulomas and, in severe cases, diffuse 
alveolar damage.30 However, these patterns 
may coexist with RA-ILD HRCT findings, 
making it difficult to distinguish between the 
two. Moreover, the clinical presentation of 
RA-ILD and methotrexate-induced 
pulmonary toxicity are very similar. Hence, it 
is crucial to consult a radiologist who is 
experienced in ILD to make the distinction of 
RA-ILD from other causes of ILD that could 
render a similar HRCT pattern. In our patient, 
a diagnosis of stand-alone methotrexate 
pneumonitis seemed unlikely as she did not 
meet the above criteria and only presented 
after many years of methotrexate therapy.
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Another factor that could complicate 
diagnosis is environmental or occupational 
exposures, which are often overlooked. It is 
stipulated that over 300 types of 
environmental triggers can increase the risk of 
developing hypersensitivity pneumonitis 
(extrinsic allergic alveolitis).31 As such, a 
thorough clinical history should address 
possible inhaled allergens at home or in the 
workplace, including pet dander, mould, dust, 
and chemicals. Patients may present similarly 
to RA-ILD with dyspnoea, cough, malaise, 
and fever.32 In long-term exposure, pulmonary 
fibrosis may also result.32 Bilateral ground-
glass opacities and/or centrilobar nodules 
often appear on HRCT, similar to that seen in 
RA-ILD.33 However, the presence of 
lymphocytosis on bronchoalveolar lavage 
(BAL) and poorly formed non-caseating 
granulomas on transbronchial biopsy are 
more suggestive of hypersensitivity 
pneumonitis, somewhat differentiating this 
from RA-ILD.31 Once a diagnosis of 
hypersensitivity pneumonitis is made, the 
avoidance of triggers and steroid therapy will 
improve symptoms. However, chronic 
damage may be irreversible. BAL would not 
differentiate between methotrexate 
pneumonitis and inhaled hypersensitivity 
pneumonitis. 
The risk of developing pulmonary malignancy 
is increased in the presence of RA-ILD and 
immunosuppression.34 Diffuse infiltrates may 
be present, indicating a haematogenous or, 
more likely, lymphangitic spread, which can 
be confirmed with BAL and transbronchial 
biopsy. Hence, in patients who do not 
respond to treatment, malignancy may be 
considered as an alternative diagnosis.20  
In addition, RA patients receiving 
immunosuppressive therapy are more 
susceptible to lower respiratory tract 
infections, especially if they have an active 
lung disease, as seen in our case. Certain 
organisms such as Mycobacterium avium, 
Mycobacterium tuberculosis, Pneumocystis jirovecii, 
and other fungal microbes have been 
identified to be responsible for causing such 
opportunistic infections and also cause a 
radiological appearance of ground-glass 
opacifications with interstitial infiltrates 
similar to that in RA-ILD.20 In essence, all 
infective complications have to be 
investigated thoroughly and managed with the 
necessary cessation of immunosuppressive 
therapy and commencement of the relevant 
antibiotics according to the results of routine 
blood, urine, and BAL cultures.  
Management of RA-ILD 
According to the British Thoracic Society 
(BTS) guidelines published in 2008,23 the 
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initial treatment of RA-ILD is typically with 
oral prednisolone at an initial dose of 0.5–
1 mg/kg/day over a period of 1–3 months. 
This is then tapered down to a maintenance 
dose of 10 mg/day or 20 mg on alternate days 
and administered with immunosuppressants 
such as cyclophosphamide,35 azathioprine,36 
penicillamine,36 or methotrexate according to 
clinical response. Immunosuppressants have 
to be evaluated in line with response to 
steroids.  
If the corticosteroids or immunosuppressants 
have failed, ciclosporin is effective as a 
steroid-sparing or adjuvant agent.36-37 
Cyclophosphamide has been found to be 
therapeutic in methotrexate-induced 
pneumonitis that has not been responsive to 
the usual methotrexate discontinuation, 
oxygen therapy, and/or corticosteroids.38  
Due to the lack of controlled studies, optimal 
treatment of RA-ILD remains a matter of 
debate. A recent update on the management 
of RA-ILD suggests that patients can be 
broadly divided into 3 groups based on the 
extent of their disease, and this determines 
their treatment40 (Figure 4), which is generally 
directed at disease control and treatment 
corresponding to histopathologic subtype. 
The first group comprises patients with 
asymptomatic ILD, whose pulmonary 
function and symptoms have to be monitored 
closely. If these are stable with no evidence of 
disease progression, then no specific therapy 
is indicated. The second group of patients 
includes those who are initially stable and 
asymptomatic but later experience progressive 
chest symptoms and a decline in lung 
function. Notably, most of these patients will 
still display limited disease signs on baseline 
HRCT. For this group, treating their 
pulmonary condition, in addition to a single 
or combined DMARD therapy for their joint 
disease, is the priority. If severe articular 
disease (disease activity score (DAS28) > 5.1) 
is evident, patients may benefit from biologic 
agents such as rituximab. In the absence of 
severe articular disease, the use of 
mycophenolate mofetil (1–2 g once daily) with 
or without acetylcysteine (600 mg three times 
daily) has been recommended.  
The final group of patients are those with 
rapidly progressive or extensive RA-ILD 
involving more than 20% of the lungs. The 
first-line treatment is 6 cycles of intravenous 
cyclophosphamide 10–15 mg/kg in 
combination with methylprednisolone 7–
10 mg/kg at 4–6-week intervals. Occasionally, 
mesna is prescribed to reduce the risk of 
haemorrhagic cystitis and later on, bladder 
cancer as a result of urothelial toxicity from 
cyclophosphamide therapy. Co-trimoxazole 
960 mg three times daily may also be 
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prescribed as prophylaxis against 
pneumocystis pneumonia, and anticoagulation 
is commenced in patients with proven 
pulmonary embolism.  Lung function has to 
be reassessed with repeat PFTs and HRCT 
post-treatment. 
Most patients put on this treatment regimen 
have been found to exhibit clinical 
improvement and stability.39 However, 
prognosis is poor in patients whose condition 
worsens further, and lung transplants may be 
considered in patients with advanced disease 
(DLco < 40% predicted) or progressive (≥ 
10% decline in FVC or ≥ 15% decline in FVC 
within 6 months of follow-up). Generally, 
patients over the age of 65 years and/or those 
with significant comorbidities are excluded 
from this criterion.23,39  
Figure 4. Algorithm of the proposed therapeutic 
approach to patients with RA-ILD (Adapted from 
White et al 28) 
 
Other ancillary treatments include annual 
influenza and pneumococcal vaccinations, 
which help prevent respiratory infections in 
RA-ILD patients, home oxygen support,23 and 
smoking cessation with nicotine replacement 
therapy or buproprion.  
Determining response to treatment is essential 
in monitoring therapeutic response and 
deciding how to manage patients further. 
Travis et al.40 has defined this as a “10% 
improvement in the forced vital capacity 
(FVC) or 15% improvement in the DLco at 12 
weeks”. Furthermore, HRCT is used to assess 
the response to treatment further by 
measuring the extent of lung involved. PFTs 
should be repeated annually and HRCT 
should only be done once every 2 years to 
minimize patients’ exposure to radiation. 
Prognosis of RA-ILD 
RA-ILD is often associated with a poor 
prognosis, which largely depends on patients’ 
age at the time of diagnosis and disease 
severity. Survival after diagnosis of RA-ILD 
has been estimated to be a median of 
approximately 3.5–5 years,41 with a mean of 3 
years,27 and these figures have been relatively 
constant over the last 30 years. In addition, 
the type of ILD pattern illustrated on HRCT 
is an important determinant of prognosis and 
survival.42 The majority of patients with RA-
ILD have either UIP or NSIP.21 UIP conveys 
the worst prognosis,43,44 whereas patients with 
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NSIP carry a better prognosis and response to 
treatment, with the cellular subtype associated 
with higher survival rates as compared to the 
fibrotic subtype. COP (rarer) also displays a 
better prognosis and is more responsive to 
oral corticosteroid therapy.4,5 Other indicators 
of poor prognosis include a low DLco (< 
54%), desaturation (< 88%), extensive 
fibrosis, and extensive disease on HRCT.21   
Conclusion 
The evidence available to guide management 
of RA-ILD remains limited. Our patient’s 
ILD was difficult to manage due to 
uncertainties regarding its true aetiology, as 
there were similarities in clinical presentation.  
Moreover, radiological scans could not 
differentiate clearly between causes of ILD. 
Continuation on methotrexate could 
exacerbate our patient’s lung disease but 
withdrawal of treatment could cause a relapse 
in her arthritis. At this point, there has been 
some clinical improvement in her symptoms 
on the tapering course of steroids and 
cessation of methotrexate therapy. However, 
her pulmonary damage is irreversible, 
suggesting it was RA-related ILD and not any 
other reversible causes, and her future 
management will thus involve 
multidisciplinary team input and is directed by 
her response to current treatment. This 
involves striking a balance between joint and 
pulmonary disease control, as well as 
rendering supportive care, with the aim of 
slowing down disease progression and 
managing her symptoms.  
Newer medications such as mycophenolate 
mofetil, rituximab, and cyclophosphamide, 
and the emergence of newer biologic agents 
have provided a positive outlook for this 
disease. However, much research remains to 
be done in evaluating current treatment 
standards, developing new pharmacotherapy, 
and screening RA patients to detect 
pulmonary disease early.  
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Learning Points 
What is known already known 
 ILD is strongly associated with Rheumatoid Arthritis and its anti-rheumatic medications, 
such as methotrexate.  
 ILD is usually treated with a tapering course of corticosteroids and/or 
immunosuppressants and managed holistically with ancillary treatments.  
What this study adds 
 The inclusion of a number of new agents (e.g. mycophenolate mofetil, rituximab, and 
cyclophosphamide) has provided a better outlook in treating ILD. Thorough 
consideration must be given to each individual patient’s extent of disease, rate of 
progression and co-morbidities when deciding which treatments to administer. 
 Prompt treatment delays disease progression of RA-ILD of arthritis and management 
revolves around symptom control. 
 
 Multidisciplinary holistic care ensures best practice. 
 Res Medica 2014, Volume 22, Issue 1               
Tan, TSE. Interstitial Lung Disease in Rheumatoid Arthritis: A Clinical Dilemma. Res Medica 2014, 22(1), pp. 88-101.  
doi:10.2218/resmedica.v22i1.732  
99 
References  
1. Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, et al. Interstitial lung disease in recent onset rheumatoid 
arthritis. Am J Respir Crit Care Med. 1997 Aug;156(2 pt 1):528-35. DOI: 10.1164/ajrccm.156.2.9609016. 
2. Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in 
rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003 Aug;62(8):722-27. DOI: 
10.1136/ard.62.8.722. 
3. Young A, Koduri, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in 
the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007 
Feb;46(2):350-7. DOI: 10.1093/rheumatology/kel253. 
4. McDonagh J, Greaves M, Wright AR, Heycock C, Owen JP, Kelly C. High resolution computed tomography of the 
lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol. 1994 Feb;33(2):118-22. DOI: 
10.1093/rheumatology/33.2.118. 
5. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease 
in rheumatoid arthritis. Arch Intern Med. 2008 Jan 28;168(2);159-66. DOI: 10.1001/archinternmed.2007.59. 
6. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, et al. Smoking 
is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope 
alleles. Ann Rheum Dis. 2006 Mar;65(3):366-71. DOI: 10.1136/ard.2005.041079. 
7. Weyand CM, Schimdt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. 
Arthritis Rheum. 1998 May;41(5),817-22. DOI: 10.1002/1529-0131(199805)41:5<817::AID-ART7>3.0.CO;2-S. 
8. Turesson C, Jacobsson LTH. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J 
Rheumatol. 2004;33(2):65-72. DOI: 10.1080/03009740310004621. 
9. Sugiyama Y, Ohmo S, Kano S, Maeda H, Kitamura S. Diffuse panbronchiolitis and rheumatoid arthritis: a possible 
correlation with HLA-B54. Intern Med. 1994;33(10):612-4. DOI: 10.2169/internalmedicine.33.612. 
10. Charles PJ, Sweatman MC, Marckwick JR, Maini RN. HLA-B40: a marker for susceptibility to lung disease in 
rheumatoid arthritis. Dis Markers. 1991 Mar-Apr;9(2):97-101.  
11. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoriou K, Sakkas LI. Anti-cyclic citrullinated peptide-
2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin 
Rheumatol. 2008 Apr;27(4):511-3. DOI: 10.1007/s10067-007-0800-1. 
12. Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol. 2008 May;20(3):340-6. 
DOI: 10.1097/BOR.0b013e3282f798ed. 
13. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti-cyclic citrullinated peptide antibodies in lung 
diseases associated with rheumatoid arthritis. Clin Biochem. 2008 Sep;41(13):1074-7. DOI: 
10.1016/j.clinbiochem.2008.06.014. 
14. McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk—
what is the evidence? Rheumatology (Oxford). 2009 Aug;48(8):867-71. DOI: 10.1093/rheumatology/kep101. 
15. Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. Can Respir J. 2013 
May-Jun;20(3):153-5.  
16. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 
2004 Feb;43(2):143-7. DOI: 10.1093/rheumatology/keg466. 
17. Kremer JM, Alarcón GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, 
radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid 
arthritis: a multicenter study with literature review. Arthritis Rheum. 1997 Oct;40(10):1829-37. DOI: 
10.1002/art.1780401016. 
18. Kelly C, Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin 
Pharmacother. 2008 Dec;9(18):3221-30. DOI: 10.1517/14656560802591430. 
19. Gaffo AL, Alarcón GS. Methotrexate is not associated with progression of interstitial lung disease in rheumatoid 
arthritis. Arch Intern Med. 2008 Sep 22;168(17):1927-8. DOI: 10.1001/archinte.168.17.1927. 
 Res Medica 2014, Volume 22, Issue 1               
Tan, TSE. Interstitial Lung Disease in Rheumatoid Arthritis: A Clinical Dilemma. Res Medica 2014, 22(1), pp. 88-101.  
doi:10.2218/resmedica.v22i1.732  
100 
20. Hamblin MJ, Horton MR. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med. 
2011;2011:872120. DOI: 10.1155/2011/872120. 
21. Lake F, Proudman S, Rheumatoid arthritis and lung disease: from mechanism to a practical approach. Semin Respir 
Crit Care Med. 2014 Apr;35(2):222-38. DOI:  10.1055/s-0034-1371542. 
22. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. J Rheumatol. 1987 
Dec;14(6):1164-71. 
23. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: 
The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish 
Thoracic Society. Thorax. 2008;63 Suppl 5:v1-58. DOI: 10.1136/thx.2008.101691. 
24. Sathi N, Urwin T, Desmond S, Dawson JK. Patients with limited rheumatoid arthritis-related interstitial lung disease 
have a better prognosis than those with extensive disease. Rheumatology. 2011 Mar;50(3) 620. 
DOI:10.1093/rheumatology/keq426. 
25. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic 
sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54.  DOI: 
10.1164/rccm.200706-877OC. 
26. Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT 
findings. Radiology. 2004 Jul;232(1):81-91. DOI: 10.1148/radiol.2321030174. 
27. Akira M, Sakatani M, Hara H. Thin-section CT findings in rheumatoid arthritis associated lung disease: CT patterns 
and their courses. J Comput Assist Tomogr. 1999 Nov-Dec;23(6):941-8. DOI: 10.1097/00004728-199911000-00021. 
28. White ES, Tazelaar HD, Lynch JP 3rd. Bronchiolar complications of connective tissue diseases. Semin Respir Crit Care 
Med. 2003 Oct;24(5):543-66. DOI: 10.1055/s-2004-815603. 
29. Ooi A, Ivenger S, Ferguson J, Ritchie AJ. VATS lung biopsy in suspected, diffuse interstitial lung disease provides, 
and alters management strategies. Heart Lung Circ. 2005 Jun;14(2):90-2. DOI: 10.1016/j.hlc.2005.01.002 
30. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and 
histopathological findings in nine patients. Eur Respir J. 2000 Feb;15(2):373-81. DOI: 10.1034/j.1399-
3003.2000.15b25.x 
31. Selman M. Hypersensitivity pneumonitis: a multifaceted deceiving disorder. Clin Chest Med. 2004 Sep;25(3):531-47. 
DOI:10.1016/j.ccm.2004.04.001. 
32. Yi ES. Hypersensitivity pneumonitis. Crit Rev Clin Lab Sci. 2002 Nov;39(6):581-629. DOI: 
10.1080/10408360290795583. 
33. Glazer CS, Rose CS, Lynch DA. Clinical and radiologic manifestations of hypersensitivity pneumonitis. J Thorac 
Imaging. 2002 Oct;17(4):261-72. DOI: 10.1097/00005382-200210000-00003. 
34. Rajasekaran A, Shovlin D, Saravanan V, Lord P, Kelly C. Interstitial lung disease in patients with rheumatoid 
arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol. 2006 Jul;33(7):1250-3.  
35. Nanki N, Fujita J, Yamaji Y, Maeda H, Kurose T, Kaji M, et al. Nonspecific interstitial pneumonia/fibrosis 
completely recovered by adding cyclophosphamide to corticosteroids. Intern Med. 2002 Oct;41(10):867-70. DOI: 
10.2169/internalmedicine.41.867. 
36. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with 
cyclosporine: a case report. J Korean Med Sci. 2002 Apr;17(2):270-3. DOI: 10.3346/jkms.2002.17.2.270. 
37. Puttick MP, Klinkhoff AV, Chalmers A, Ostrow DN. Treatment of progressive rheumatoid interstitial lung disease 
with cyclosporine. J Rheumatol. 1995 Nov;22(11):2163-5.  
38. Suwa A, Hirakata M, Satoh S, Mimori T, Utsumi K, Inada S. Rheumatoid arthritis associated with methotrexate-
induced pneumonitis: improvement with i.v. cyclophosphamide therapy. Clin Exp Rheumatol. 1999 May-
Jun;17(3):355-8. 
39. Malik S, Saravanan V, Kelly C. Interstitial lung disease in rheumatoid arthritis: an update on diagnosis and 
management. Int J Clin Rheumatol. 2012 Aug 6;7(3):297-308. DOI: 10.2217/IJR.12.24. 
40. Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR, et al. Idiopathic nonspecific interstitial 
pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008 Jun 15; 77(12):1338-47. 
 Res Medica 2014, Volume 22, Issue 1               
Tan, TSE. Interstitial Lung Disease in Rheumatoid Arthritis: A Clinical Dilemma. Res Medica 2014, 22(1), pp. 88-101.  
doi:10.2218/resmedica.v22i1.732  
101 
DOI: 10.1164/rccm.200611-1685OC. 
41. Hakala M. Poor prognoses in patients with rheumatoid arthritis hospitalized for interstitial lung 
fibrosis. Chest. 1988;93(1):114-8. DOI: 10.1378/chest.93.1.114. 
42. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of 
histopathologic and radiographic pattern. Chest. 2009 Nov;136(5):1397-405.  DOI: 10.1378/chest.09-0444. 
43. Lee HK, Kim DS, Yoo B, Seo JB, Rho JY, Colby TV, et al. Histopathologic pattern and clinical features of 
rheumatoid arthritis-associated interstitial lung disease. Chest. 2005 Jun;127(6):2019-27. DOI: 
10.1378/chest.127.6.2019. 
44. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in 
rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010 Jun;35(6):1322-8. DOI: 
10.1183/09031936.00092309.  
45. Yoo JW, Song JW, Jang SJ, Lee CK, Kim MY, Lee HK, et al. Comparison between cryptogenic organizing 
pneumonia and connective tissue disease-related organizing pneumonia. Rheumatology (Oxford). 2011 May;50(5):932-8. 
DOI: 10.1093/rheumatology/keq410. 
 
 
 
 
 
 
